好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Cerebral Hemodynamics of Patients with Chronic Migraine: Effects of the Botulinum Neurotoxin-A
Headache
P01 - (-)
085
We aimed to evaluate the changes in middle cerebral artery (MCA) and posterior cerebral artery (PCA) in terms of Mean Blood Flow Velocity, Breath-Holding-Index (BHI) and pulsatility index (PI) in patients with chronic migraiene before and after treatment with BoNTA by using TCD.
The study included 25 patients with chronic migraine. 12 patients were treated with high-dose (100 IU) BoNTA and 13 patients were treated with low-dose BoNTA (50 IU). BoNT was injected to facial, scalp and neck muscles. Mean blood flow velocity, BHI and PI were measured before and 7 days after BoNTA injection in MCA and PCA bilaterally in both groups. We compared the pre-treatment and post-treatment values. We also evaluated the Visual Analogue Scale (VAS) scores in both groups before and after-treatment.
Pulsatility index was significantly decreased in MCA (before treatment PI=0,74卤0,13, after treatment PI=0,69卤0,10) (p=0.024) and insignificantly changed in PCA after treatment in high-dose group (p>0.05). Differences in Mean blood flow velocity and BHI were insignificant in both groups in both arteries (p>0.05). VAS scores significantly decreased after treatment in both groups (p<0.001).
The PI is a well known indicator of peripheral vascular resistance. Our results suggest that BoNTA treatment may be effective by reducing the resistance in intracranial vascular beds in patients with chronic-migraine.
Authors/Disclosures
Hakan Akgun
PRESENTER 		No disclosure on file
Serdar Tasdemir, MD (Beytepe Military Hospital,) No disclosure on file
Mehmet Yucel, MD No disclosure on file
No disclosure on file
Umit H. Ulas, MD (Case Medical Center Neurology) No disclosure on file
Seref Demirkaya, PhD No disclosure on file
Yasar Kutukcu No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.